FDA accepts sBLA for Yervoy® (ipilimumab) as adjuvant treatment for stage 3 melanoma
Bristol-Myers Squibb announced the (FDA has accepted for filing and review the supplemental Biologics License Application for Yervoy for the adjuvant treatment of patients with stage 3 melanoma who are at high risk of recurrence following complete surgical resection. March 02, 2015